

#### Addiction Medication in Pharmacies (Tonko)

On page 3, at the end of the section entitled “ILLICIT DRUGS AND SUBSTANCE USE AND MISUSE”, insert this language:

*“The lack of clear guidance to pharmacies, manufacturers, and distributors from the DEA has contributed to a gap in access for patients in need of buprenorphine to treat opioid use disorder. The Committee will review the activities undertaken by the DOJ, HHS, and other agencies within the Committee’s jurisdiction, to promote the stocking of buprenorphine in pharmacies.”*